There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Star Equity Holdings (STRR – Research Report), Applied DNA Sciences (APDN – Research Report) and Dermata Therapeutics (DRMA – Research Report) with bullish sentiments.
Star Equity Holdings (STRR)
In a report released yesterday, Tate Sullivan from Maxim Group maintained a Buy rating on Star Equity Holdings, with a price target of $2.25. The company’s shares closed last Tuesday at $0.79.
According to TipRanks.com, Sullivan is a 5-star analyst with an average return of
Currently, the analyst consensus on Star Equity Holdings is a Moderate Buy with an average price target of $2.25.
See today’s best-performing stocks on TipRanks >>
Applied DNA Sciences (APDN)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Applied DNA Sciences yesterday and set a price target of $3.00. The company’s shares closed last Tuesday at $1.11, close to its 52-week low of $0.62.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Applied DNA Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $4.00, representing a 263.6% upside. In a report issued on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.
Dermata Therapeutics (DRMA)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics, with a price target of $4.00. The company’s shares closed last Tuesday at $2.60, close to its 52-week low of $0.98.
According to TipRanks.com, Vendetti ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dermata Therapeutics with a $4.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STRR:
- Star Equity Holdings, Inc. Announces 2023 First Quarter Financial Results
- Star Equity Holdings, Inc. Announces Sale of Digirad Health, Inc. for $40 Million
- Star Equity Holdings, Inc. to Release First Quarter 2023 Financial Results on May 15th
- STRR Upcoming Earnings Report: What to Expect?
- Star Equity’s KBS Builders wins $2.2M contract in Burlington, Vermont
